What is the long-term trend for Aquestive Therapeutics, Inc.'s long-term debt and finance lease obligations?

Over 3 years (2022 to 2025), Aquestive Therapeutics, Inc.'s long-term debt and finance lease obligations has grown at a -6.3% compound annual growth rate (CAGR), from $33.45M to $27.52M.

Aquestive Therapeutics, Inc. AQST Long-Term Debt and Finance Lease Obligations

Long-Term Debt and Finance Lease Obligations at other companies

AMP

Amphastar PharmaceuticalsAMPH

——

AptarGroupATR

——

AbbVieABBV

——

Other financials

Income statement

See full

Revenue$14.4M+65.7%

Gross profit$11.0M+117%

Operating income-$4.2M+78.3%

Net income-$8.1M+64.9%

EPS (diluted)-$0.07+70.8%

Balance sheet

See full

Cash & equivalents$110.7M+61.3%

Total debt$64.4M+7.4%

Total equity-$34.1M+44.1%

Total assets$141.1M+38.0%

Cash flow

See full

Operating cash flow-$14.8M+36.7%

CapEx$52.0K-61.5%

Free cash flow-$14.9M+36.9%

Valuation

See full

Market cap$560.13M+73.5%

Enterprise value$513.76M+63.6%

P/S11.1×+5.2×

Profitability

See full

Gross margin63.5%-4.9pp

Operating margin-111.2%+96.3pp

Net margin-137.1%+80.7pp

FCF margin-88.2%-2.2pp

Returns & leverage

See full

Return on equity145.1%—

Debt / equity-1.9×—

Current ratio4.1×-0.8×

Where this comes from

Reported directly by Aquestive Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:LongTermDebtAndCapitalLeaseObligations.

The official record: Aquestive Therapeutics, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Aquestive Therapeutics, Inc.'s long-term debt and finance lease obligations.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Aquestive Therapeutics, Inc.'s long-term debt and finance lease obligations?: Aquestive Therapeutics, Inc. (AQST) reported long-term debt and finance lease obligations of $25.1M in Q1 2026.
What is the long-term trend for Aquestive Therapeutics, Inc.'s long-term debt and finance lease obligations?: Over 3 years (2022 to 2025), Aquestive Therapeutics, Inc.'s long-term debt and finance lease obligations has grown at a -6.3% compound annual growth rate (CAGR), from $33.45M to $27.52M.